FAST NEWS: BlackRock boosts stake in battered WuXi AppTec
The latest: Asset management company BlackRock Inc. purchased 618,000 Hong Kong-listed shares of WuXi AppTec Co. Ltd. (2359.HK; 603259.SH) on March 26, raising its stake in the drug outsourcing services company from…
FAST NEWS: JPMorgan boosts WuXi AppTec stake
The latest: U.S. banking giant JPMorgan purchased 1.57 million Hong Kong-listed shares of WuXi AppTec Co. Ltd. (2359.HK; 603259.SH) for HK$75.33 million ($9.66 million) on Feb. 8, raising its stake in the drug…
FAST NEWS: Viva Biotech completes Langhua Pharma buyout
The latest: Viva Biotech Holdings (1873.HK) announced Thursday that the acquisition of 20% of Langhua Pharmaceutical by its Weizongchen Pharmaceutical subsidiary for 640 million yuan ($87.6 million) has been completed. Looking…
Wuxi AppTec finds bitter aftertaste in waning demand for Covid drug services
The leading Chinese CXO posted record revenue and strong profits last year, but its growth started to slow in the fourth quarter Key Takeaways: Wuxi AppTec’s chemical business doubled last…
FAST NEWS: WuXi AppTec’s Operating Profit Doubles in First Quarter
The latest: Pharmaceutical services outsourcing company WuXi AppTec Co. Ltd. (2359.HK; 603259.SH) forecast it will post a net profit of about 1.64 billion yuan ($258 million) in the first quarter, up…
FAST NEWS: Viva Biotech Finds First Profits in Drug Research Services
The latest: Viva Biotech Holdings (1873.HK) announced it earned a net profit of 287 million yuan ($45 million) last year, reversing a 386 million yuan loss in 2020, equating to earnings of…
FAST NEWS: Drug Discovery Business Helps Viva Biotech Swing Back to Profit
The latest: Viva Biotech Holdings (1873.HK) released a positive profit forecast, saying it posted a net profit of 300 million yuan ($48.2 million) or more last year, reversing a loss…
Recent Articles
FAST NEWS: BlackRock boosts stake in battered WuXi AppTec
2359.HK
603259.SHG
FAST NEWS: JPMorgan boosts WuXi AppTec stake
2359.HK
603259.SHG
Wuxi AppTec finds bitter aftertaste in waning demand for Covid drug services
2359.HK
603259.SHG
RELATED ARTICLES
-
WuXi Biologics hatches new baby with ADC drug unit IPO
2269.HK -
Potential U.S. targeting casts shadow over WuXi AppTec family
2359.HK 603259.SHG
-
FAST NEWS: JPMorgan boosts WuXi AppTec stake
2359.HK 603259.SHG
-
WuXi Bio prescribes share buyback to relieve revenue pain
2269.HK
-
FAST NEWS: WuXi Biologics boosts new projects target
2269.HK
- CHINA BULLETIN: Local Governments Crushed by Debt
